Alexander Streuer, Johann-Christoph Jann, Tobias Boch, Maximilian Mossner, Vladimir Riabov, Nanni Schmitt, Eva Altrock, Qingyu Xu, Marie Demmerle, Verena Nowak, Julia Oblaender, Iris Palme, Nadine Weimer, Felicitas Rapp, Georgia Metzgeroth, Anna Hecht, Thomas Höger, Christian Merz, Wolf-Karsten Hofmann, Florian Nolte, Daniel Nowak
In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired erythropoiesis. Asunercept (APG101) is a novel therapeutic fusion protein blocking CD95, which has previously shown partial efficacy in reducing transfusion requirement in a clinical phase I trial for low-risk MDS patients (NCT01736436; 2012-11-26). In the current study we aimed to evaluate the effect of Asunercept therapy on the clonal bone marrow composition to identify potential biomarkers to predict response...
February 27, 2024: Annals of Hematology